5 Keys to Patient Education on GLP-1 RAs for Weight Loss
As ‘magic’ weight loss drugs capture public attention, you’ve likely seen an uptick in patients asking about GLP-1 RAs for weight loss. As your go-to partner for cardiometabolic risk reduction research, industry news, and practical strategies, we’ve created this highly practical guide to help you educate patients on safe access to GLP-1 RAs for weight […]
GLP-1 Receptor Agonist Lixisenatide Approved by US FDA
The GLP-1 receptor agonist lixisenatide has received US FDA approval for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. Approval was based on 11 clinical trials that evaluated more than 11,000 patients, including a cardiovascular outcomes trial, ELIXA, that showed no increase in adverse cardiovascular events. Efficacy studies […]
